AbbVie's Rinvoq conquers Regeneron and Sanofi's Dupixent in eczema trial—again
For the second time in four years, AbbVie’s Rinvoq (upadacitinib) has shown superior efficacy to Regeneron and Sanofi’s powerhouse Dupixent (dupilumab) in a head-to-head study in patients with atopic dermatitis (AD). In the LEVEL UP trial testing patients …